Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
ScemblixⓇ - BCR-ABL inhibitor
NCT04971226 ASC4FIRST (CABL001J12301)
Chronic myeloid leukemia, 1st line
Phase 3
Indication
Phase
Patients
402
Primary
Outcome
Measures
Arms
Major Molecular Response (MMR) at week 48
Conclusions
Intervention
Arm 1: asciminib 80 mg QD
Arm 2: Investigator selected TKI including one of the below treatments:
- Imatinib 400 mg QD
Target
Patients
- Nilotinib 300 mg BID
-
-
· Dasatinib 100 mg QD
- Bosutinib 400 mg QD
Patients with newly diagnosed philadelphia chromosome positive chronic
myelogenous leukemia in chronic phase
Readout
Milestone(s)
2024
Publication
TBD
76 Investor Relations | Q2 2023 Results
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation